Issue #7 December 2020 • 1 minute read

Welcome to VITALITY.

You’re receiving this newsletter because you’re a customer, partner, or you’ve otherwise subscribed or opted in at one of our events, conferences, or website


  • Letter from CEO, Craig Cooper.
  • New research finds home BP advantageous for diagnosing hypertension.
  • Half-yearly corporate update.
  • New executive team members.

From the Heart

Thoughts from our CEO, Craig Cooper


The start of vaccinations against COVID-19 have begun around the world bringing hope for an end to the pandemic in 2021. With remote care and telemedicine emerging as highly effective during the pandemic, the future will certainly continue to rely on home health and data gleaned from wearables.

Supporting this, a new study published in the Journal of the American College of Cardiology found one week of home blood pressure (BP) monitoring to be more reliable than ambulatory or office BP in diagnosing hypertension and its associated risk of cardiovascular disease.

To close out a 2020 on a high note, we are excited to welcome two key leaders to our team, Steven Kesten, MD who joins as Chief Medical Officer and Mark Gorelick, PhD, who joins as Chief Product Officer. From everyone on our team, we wish you a happy, healthy, and successful new year!

Stay healthy, stay strong,


Study Highlights Advantages of Home BP Monitoring


Hypertension is the world’s leading risk factor for cardiovascular disease but many people do not know that they have blood pressure. With home monitoring becoming more widely used, a new study from the Journal of the American College of Cardiology compared office blood pressure (OBP), ambulatory BP (ABP), and home BP (HBP) to assess which is best for diagnosing hypertension. They found that home BP was more reliable and also required fewer resources, time, and personnel. Read the full study here.

Half-Yearly Corporate and Sales Update


ATCOR’s parent company, CardieX Limited, recently shared its half-yearly performance update with investors. ATCOR reported the strongest H1 sales results for the Company over the last five years and a more than 30% increase in sales over the same period last year. Full details are available here.

Chief Medical Officer and Chief Product Officer Join Our Executive Team


This month we welcomed two highly experienced executives to our team – Steven Kesten, MD and Mark Gorelick, PhD. Steven joins us as our new Chief Medical Officer and will be focused on developing and leading our clinical advocacy and payer programs as well as assisting in the development of new clinical products and solutions. Mark, a recognized innovator with deep biomedical and digital health experience, will lead our product development and delivery across the expanse of new products currently in development in wearables, home, and clinical devices.

Get In Touch


We’d love to hear from you

About Us

ATCOR is the world leader in medical devices for measuring arterial stiffness and central blood pressure waveforms based on its unique FDA-cleared and patented SphygmoCor® technology. Under the ATCOR·X brand, the company also develops and licenses physiological and health analytics for wearable devices for medical and consumer applications. The company’s digital platform, ArtyNet™, is a connected SaaS ecosystem providing physicians with a complete telehealth solution for remotely managing patients’ health (2021 launch). ATCOR is a subsidiary of CardieX Limited, which is listed on the Australian Stock Exchange (ASX:CDX).